Trial Profile
A Double Blind, Randomized Four Way Cross Over Study to Compare the Effect of Fesoterodine 4mg and 8mg Once Daily and Oxybutynin 5mg Twice Daily After Steady State Dosing Versus Placebo on Cognitive Function in Subjects With Overactive Bladder, Over the Age of 75 Years With Mild Cognitive Impairment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2020
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary) ; Oxybutynin
- Indications Mild cognitive impairment; Overactive bladder
- Focus Therapeutic Use
- 18 Feb 2020 Status changed from recruiting to completed.
- 04 Dec 2019 Planned End Date changed from 1 Dec 2019 to 1 Jan 2020.
- 04 Dec 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Jan 2020.